Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥ 18 years of age~* Diagnosis of at least probable idiopathic inflammatory myopathies (IIM) per European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria which includes confirmation of dermatomyositis (DM) rash/manifestation, disease activity defined by presence of DM rash / manifestation or an objective disease activity measure~* Disease severity defined by Physician global activity visual analog scale (VAS) with a minimum value of 2.0 cm on a 10 cm scale and MMT-8 ≤ 142 or CDASI total activity score ≥ 14.~* Corticosteroid daily dose less than that or equal to 20 mg prednisolone equivalent~Exclusion Criteria:~* Cancer-associated myositis~* Evidence of active malignant disease or malignancies diagnosed within the previous 5 years~* Physician Global Damage score ≥ 3, or clinically relevant improvement between Screening Visit and Baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): human immunoglobulin G administered subcutaneously
- Placebo (Type: PLACEBO_COMPARATOR): human albumin solution administered subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).